标题
PPAR agonists for the treatment of cardiovascular disease in patients with diabetes
作者
关键词
-
出版物
DIABETES OBESITY & METABOLISM
Volume 14, Issue 11, Pages 973-982
出版商
Wiley
发表日期
2012-03-24
DOI
10.1111/j.1463-1326.2012.01601.x
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome
- (2011) Barbara C Hansen et al. Cardiovascular Diabetology
- Rosiglitazone and the Risk of Adverse Cardiovascular Outcomes
- (2011) A G Winterstein CLINICAL PHARMACOLOGY & THERAPEUTICS
- A new, highly selective murine peroxisome proliferator-activated receptor δ agonist increases responsiveness to thermogenic stimuli and glucose uptake in skeletal muscle in obese mice
- (2011) R. A. Ngala et al. DIABETES OBESITY & METABOLISM
- The safety of thiazolidinediones
- (2011) Keith G Tolman Expert Opinion On Drug Safety
- National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants
- (2011) Mariel M Finucane et al. LANCET
- Comparative Gene Expression Profiles Induced by PPARγ and PPARα/γ Agonists in Human Hepatocytes
- (2011) Alexandra Rogue et al. PLoS One
- Therapeutic Potential of Aleglitazar, a New Dual PPAR-α/γ Agonist
- (2010) Matthew A. Cavender et al. American Journal of Cardiovascular Drugs
- Pharmacokinetics, Pharmacodynamics, and Tolerability of Aleglitazar in Patients With Type 2 Diabetes: Results From a Randomized, Placebo-Controlled Clinical Study
- (2010) P Sanwald-Ducray et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Cardiovascular risk and thiazolidinediones-what do meta-analyses really tell us?
- (2010) G. Schernthaner et al. DIABETES OBESITY & METABOLISM
- Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study
- (2010) T. M. E. Davis et al. DIABETOLOGIA
- Effects of PPARγ on hypertension, atherosclerosis, and chronic kidney disease
- (2010) Akira Sugawara et al. ENDOCRINE JOURNAL
- Effects of high dose aleglitazar on renal function in patients with type 2 diabetes
- (2010) Matthias Herz et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Risk of Acute Myocardial Infarction, Stroke, Heart Failure, and Death in Elderly Medicare Patients Treated With Rosiglitazone or Pioglitazone
- (2010) David J. Graham et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Selective modulation of PPARγ activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with Type 2 diabetes
- (2010) Fredrick L. Dunn et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Regulatory Action on Rosiglitazone by the U.S. Food and Drug Administration
- (2010) Janet Woodcock et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Gene Expression Changes Induced by PPAR Gamma Agonists in Animal and Human Liver
- (2010) Alexandra Rogue et al. PPAR Research
- Coactivators in PPAR-Regulated Gene Expression
- (2010) Navin Viswakarma et al. PPAR Research
- Harmonizing the Metabolic Syndrome
- (2009) K.G.M.M. Alberti et al. CIRCULATION
- Efficacy and safety of muraglitazar: a double-blind, 24-week, dose-ranging study in patients with type 2 diabetes
- (2009) Cindy J. Rubin et al. Diabetes & Vascular Disease Research
- Effects of Long-Term Fenofibrate Treatment on Markers of Renal Function in Type 2 Diabetes: The FIELD Helsinki substudy
- (2009) C. Forsblom et al. DIABETES CARE
- Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes
- (2009) John Dormandy et al. DRUG SAFETY
- Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study
- (2009) Robert R Henry et al. LANCET
- Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
- (2009) Philip D Home et al. LANCET
- Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: Results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10)
- (2008) Robert Wilcox et al. AMERICAN HEART JOURNAL
- Effect of Fenofibrate on Kidney Function: A 6-Week Randomized Crossover Trial in Healthy People
- (2008) Jean-Claude Ansquer et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Fat and Beyond: The Diverse Biology of PPARγ
- (2008) Peter Tontonoz et al. Annual Review of Biochemistry
- Impact of peripheral arterial disease in patients with diabetes—Results from PROactive (PROactive 11)
- (2008) J.A. Dormandy et al. ATHEROSCLEROSIS
- Fibrate Therapy
- (2008) Joshua Remick et al. Cardiology in Review
- Decrease of peroxisome proliferator-activated receptor delta expression in cardiomyopathy of streptozotocin-induced diabetic rats
- (2008) B.-C. Yu et al. CARDIOVASCULAR RESEARCH
- New Drugs for the Treatment of Diabetes Mellitus
- (2008) Darren K. McGuire et al. CIRCULATION
- Physiogenomic comparison of edema and BMI in patients receiving rosiglitazone or pioglitazone
- (2008) Gualberto Ruaño et al. CLINICA CHIMICA ACTA
- Improvement of glycaemic and lipid profiles with muraglitazar plus metformin in patients with type 2 diabetes: an active-control trial with glimepiride
- (2008) Cindy J Rubin et al. Diabetes & Vascular Disease Research
- Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies
- (2008) Theodore Mazzone et al. LANCET
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Intensive Glucose Lowering in Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes
- (2008) William Duckworth et al. NEW ENGLAND JOURNAL OF MEDICINE
- Urothelial Carcinogenesis in the Urinary Bladder of Rats Treated with Naveglitazar, a γ-dominant PPAR α/γ Agonist: Lack of Evidence for Urolithiasis as an Inciting Event
- (2008) Gerald G. Long et al. TOXICOLOGIC PATHOLOGY
- Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head-to-Head Randomized Clinical Studies
- (2008) Mark A. Deeg et al. PPAR Research
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now